2 weeks Ago By Defense World Staff
Rhumbline Advisers cut its position in shares of Aclaris Therapeutics, Inc. ( NASDAQ:ACRS – Free Report ) by 56.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 42,005 shares of the biotechnology company’s stock after selling 55,215 shares during the period. Rhumbline Advisers owned 0.06% of Aclaris Therapeutics worth $46,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Bain Capital Life Sciences Investors LLC increased its holdings in Aclaris Therapeutics by 2.9% in the fourth quarter.
Bain Capital Life Sciences Investors LLC now owns 3,500,000 shares of the biotechnology company’s stock worth $3,675,000 after buying an additional 100,000 shares during the last quarter. Octagon Capital Advisors LP bought a new position in shares of Aclaris Therapeutics during the 4th quarter valued at $105,000. Mirae Asset Global Investments Co.
Ltd. bought a new position in shares of Aclaris Therapeutics during the 1st quarter valued at $39,000. BNP Paribas Financial Markets lifted its stake in shares of Aclaris Therapeutics by 10.
9% in the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 23,747 shares during the last quarter. Finally, Deuterium Capital Management LLC bought a new stake in Aclaris Therapeutics in the first quarter worth $99,000.
98.34% of the stock is currently owned by institutional investors and hedge funds. Aclaris Therapeutics Stock Down 1.
7 % Shares of NASDAQ:ACRS opened at $1.15 on Tuesday. The company has a market cap of $81.
95 million, a price-to-earnings ratio of -1.06 and a beta of 0.21.
The business has a 50 day moving average price of $1.21 and a 200 day moving average price of $1.20.
Aclaris Therapeutics, Inc. has a twelve month low of $0.59 and a twelve month high of $6.
98. Analysts Set New Price Targets A number of analysts have weighed in on the company. StockNews.
com raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 25th. HC Wainwright reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a research report on Tuesday, September 17th. Seven equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company.
According to data from MarketBeat.com, Aclaris Therapeutics has an average rating of “Hold” and a consensus price target of $23.00.
Read Our Latest Stock Analysis on Aclaris Therapeutics Insiders Place Their Bets In related news, major shareholder Braden Michael Leonard bought 123,017 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, July 5th. The stock was acquired at an average price of $1.15 per share, for a total transaction of $141,469.
55. Following the completion of the purchase, the insider now owns 13,447,969 shares in the company, valued at $15,465,164.35.
The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . Insiders have purchased 588,068 shares of company stock worth $726,507 in the last ninety days. Insiders own 6.
40% of the company’s stock. Aclaris Therapeutics Profile ( Free Report ) Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research.
The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Featured Articles Five stocks we like better than Aclaris Therapeutics Dividend Payout Ratio Calculator TJX Stock: A Buying Opportunity Before the Holiday Rush 3 Home Improvement Stocks that Can Upgrade Your Portfolio Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge How to Use High Beta Stocks to Maximize Your Investing Profits Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
